Patents by Inventor Harald Mottl

Harald Mottl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
    Publication number: 20160319027
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: April 6, 2016
    Publication date: November 3, 2016
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Adrian WALMSLEY, Harald MOTTL
  • ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
    Publication number: 20150183885
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: December 5, 2014
    Publication date: July 2, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Adrian Walmsley, Harald Mottl
  • TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES
    Publication number: 20130084285
    Abstract: The invention relates to a formulation of an anti-?2 integrin antibody for administration to a patient, which is suitable for the treatment of cancer.
    Type: Application
    Filed: August 23, 2012
    Publication date: April 4, 2013
    Applicant: GLENMARK PHARMACEUTICALS, S.A.
    Inventor: Harald Mottl
  • Treatment with anti-alpha2 integrin antibodies
    Patent number: 8298531
    Abstract: The invention relates to treatment of cancer.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: October 30, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventor: Harald Mottl
  • Humanized antibodies specific for von Willebrand factor
    Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES
    Publication number: 20100158904
    Abstract: The invention relates to treatment of cancer.
    Type: Application
    Filed: November 6, 2009
    Publication date: June 24, 2010
    Applicant: GLENMARK PHARMACEUTICALS, S.A.
    Inventor: Harald Mottl
  • Stabilized aqueous solutions of ergoline compounds
    Publication number: 20090239894
    Abstract: The present invention relates to stabilized aqueous solutions of an ergoline compound of formula I or their physiologically tolerable salt or derivative, in which R1 stands for an H atom or a halogen atom and R2 stands for an alkyl group or alkenyl group with 1 to 4 carbons and a single or double bond, also containing 0.05% to 90.00% of at least one oxygen-containing cosolvent. Likewise, the present invention relates to the use of the solutions stabilized according to the present invention to prepare an agent for parenteral treatment of neurodegenerative diseases or brain trauma.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 24, 2009
    Inventors: Bjorn Schurad, Harald Mottl
  • HUMANIZED ANTIBODIES SPECIFIC FOR VON WILLEBRAND FACTOR
    Publication number: 20090232804
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Application
    Filed: January 23, 2009
    Publication date: September 17, 2009
    Applicant: GLENMARK PHARMACEUTICALS, S.A.,
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger